412 related articles for article (PubMed ID: 35091452)
1. Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56
Veneziani I; Alicata C; Pelosi A; Landolina N; Ricci B; D'Oria V; Fagotti A; Scambia G; Moretta L; Maggi E
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091452
[TBL] [Abstract][Full Text] [Related]
2. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production.
Hart OM; Athie-Morales V; O'Connor GM; Gardiner CM
J Immunol; 2005 Aug; 175(3):1636-42. PubMed ID: 16034103
[TBL] [Abstract][Full Text] [Related]
3. Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells.
Takahashi E; Kuranaga N; Satoh K; Habu Y; Shinomiya N; Asano T; Seki S; Hayakawa M
Scand J Immunol; 2007 Feb; 65(2):126-38. PubMed ID: 17257217
[TBL] [Abstract][Full Text] [Related]
4. CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation.
Romagnani C; Juelke K; Falco M; Morandi B; D'Agostino A; Costa R; Ratto G; Forte G; Carrega P; Lui G; Conte R; Strowig T; Moretta A; Münz C; Thiel A; Moretta L; Ferlazzo G
J Immunol; 2007 Apr; 178(8):4947-55. PubMed ID: 17404276
[TBL] [Abstract][Full Text] [Related]
5. CD56
Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
Front Immunol; 2019; 10():14. PubMed ID: 30761123
[TBL] [Abstract][Full Text] [Related]
6. ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/- natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
Huth TK; Staines D; Marshall-Gradisnik S
J Transl Med; 2016 Apr; 14():97. PubMed ID: 27098723
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of a tumor infiltrating CD56(+)/CD16 (-) NK cell subset with specificity for pancreatic and prostate cancer cell lines.
Frankel TL; Burns W; Riley J; Morgan RA; Davis JL; Hanada K; Quezado M; Rosenberg SA; Royal RE
Cancer Immunol Immunother; 2010 Dec; 59(12):1757-69. PubMed ID: 20734041
[TBL] [Abstract][Full Text] [Related]
8. A CD8α(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities.
Vargas-Inchaustegui DA; Demberg T; Robert-Guroff M
Immunology; 2011 Nov; 134(3):326-40. PubMed ID: 21978002
[TBL] [Abstract][Full Text] [Related]
9. The early expansion of anergic NKG2A
Roberto A; Di Vito C; Zaghi E; Mazza EMC; Capucetti A; Calvi M; Tentorio P; Zanon V; Sarina B; Mariotti J; Bramanti S; Tenedini E; Tagliafico E; Bicciato S; Santoro A; Roederer M; Marcenaro E; Castagna L; Lugli E; Mavilio D
Haematologica; 2018 Aug; 103(8):1390-1402. PubMed ID: 29700172
[TBL] [Abstract][Full Text] [Related]
10. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.
Cooper MA; Fehniger TA; Turner SC; Chen KS; Ghaheri BA; Ghayur T; Carson WE; Caligiuri MA
Blood; 2001 May; 97(10):3146-51. PubMed ID: 11342442
[TBL] [Abstract][Full Text] [Related]
11. CD56
Wang H; Zeng Y; Zhang M; Ma H; Xu B; Jiang H; Wang J; Li G
Hum Immunol; 2019 Oct; 80(10):871-877. PubMed ID: 31326139
[TBL] [Abstract][Full Text] [Related]
12. Human toll-like receptor 8 (TLR8) in NK cells: Implication for cancer immunotherapy.
Veneziani I; Alicata C; Moretta L; Maggi E
Immunol Lett; 2023 Sep; 261():13-16. PubMed ID: 37451320
[TBL] [Abstract][Full Text] [Related]
13. NK cells and the profile of inflammatory cytokines in the peripheral blood of patients with advanced carcinomas.
Saito LM; Ortiz RC; Amôr NG; Lopes NM; Buzo RF; Garlet GP; Rodini CO
Cytokine; 2024 Feb; 174():156455. PubMed ID: 38043142
[TBL] [Abstract][Full Text] [Related]
14. Natural Killer Cells Generated From Human Induced Pluripotent Stem Cells Mature to CD56
Euchner J; Sprissler J; Cathomen T; Fürst D; Schrezenmeier H; Debatin KM; Schwarz K; Felgentreff K
Front Immunol; 2021; 12():640672. PubMed ID: 34017328
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of peripheral blood NK cell subsets and cytokines in unexplained recurrent miscarriage.
Adib Rad H; Basirat Z; Mostafazadeh A; Faramarzi M; Bijani A; Nouri HR; Soleimani Amiri S
J Chin Med Assoc; 2018 Dec; 81(12):1065-1070. PubMed ID: 30145058
[TBL] [Abstract][Full Text] [Related]
16. CD16- CD56+ natural killer cells after bone marrow transplantation.
Jacobs R; Stoll M; Stratmann G; Leo R; Link H; Schmidt RE
Blood; 1992 Jun; 79(12):3239-44. PubMed ID: 1375847
[TBL] [Abstract][Full Text] [Related]
17. Accessory-cell-mediated activation of porcine NK cells by toll-like receptor 7 (TLR7) and TLR8 agonists.
Toka FN; Nfon CK; Dawson H; Golde WT
Clin Vaccine Immunol; 2009 Jun; 16(6):866-78. PubMed ID: 19369481
[TBL] [Abstract][Full Text] [Related]
18. Expanded CD56
Poznanski SM; Nham T; Chew MV; Lee AJ; Hammill JA; Fan IY; Butcher M; Bramson JL; Lee DA; Hirte HW; Ashkar AA
Cancer Immunol Res; 2018 Oct; 6(10):1174-1185. PubMed ID: 30018043
[TBL] [Abstract][Full Text] [Related]
19. A New Hope for CD56
Forconi CS; Oduor CI; Oluoch PO; Ong'echa JM; Münz C; Bailey JA; Moormann AM
Front Cell Infect Microbiol; 2020; 10():162. PubMed ID: 32373555
[TBL] [Abstract][Full Text] [Related]
20. Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12.
Dowell AC; Oldham KA; Bhatt RI; Lee SP; Searle PF
Cancer Immunol Immunother; 2012 May; 61(5):615-28. PubMed ID: 22021067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]